Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis
Viruses · 2023
DOI: 10.3390/v15071489 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Viruses, 2023. Verfasst von Pooja Devan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in DAA-experienced CHC patients remains sparse. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of SOF/VEL/VOX as a salvage treatment in DAA-experienced CHC patients. We searched five electronic databases from inception to 31 January 2023. The study outcomes were SVR12 and treatment-related adverse effects, with subgroup analysis performed based on genotype, cirrhosis, HCC, prior SOF/VEL exposure, and region. We identified and analyzed data from 24 studies (2877 DAA-experienced CHC patients); 17.2% had prior SOF/VEL exposure, 25% received ribavirin with SOF/VEL/VOX, and 42% had pre-treatment resistance-associated substitution (RAS) testing performed. Eastern Mediterranean had a higher pooled SVR12 than the America and Europe regions (p < 0.05). Predictors of SOF/VEL/VOX failure were genotype 3, active HCC, baseline cirrhosis, and prior SOF/VEL. Baseline RAS mutation and ribavirin supplementation were not associated with higher SVR12. Treatment discontinuation because of drug-related adverse events was uncommon (10 studies, 0.2%). In summary, SOF/VEL/VOX is efficacious and safe for retreatment in DAA-experienced CHC patients, even with RAS mutation. Our findings support SOF/VEL/VOX as a first-line rescue treatment for DAA-experienced CHC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore.
- Division of Gastroenterology & Hepatology, University of Utah Health, Salt Lake City, UT 84112, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA.
- Education Resource Centre, Medical Board, Singapore General Hospital, Singapore 169608, Singapore.
- Department of Mental Health and Preventive Medicine, University of Campania "L. Vanvitelli", 81100 Napoli, Italy.
- Clinical Institute of Fundeni, Gastroenterology and Hepatology, 022328 Bucharest, Romania.
ORCID-Profile: Karn Wijarnpreecha, Nicola Coppola, Yu Jun Wong
Zitieren
APA
Devan, P., Tiong, K. L. A., Neo, J. E., Mohan, B. P., Wijarnpreecha, K., Tam, Y. C. S., Coppola, N., Preda, C. M., & Wong, Y. J. (2023). Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. Viruses. https://doi.org/10.3390/v15071489
Vancouver
Devan P, Tiong KLA, Neo JE, Mohan BP, Wijarnpreecha K, Tam YCS, et al. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. Viruses. 2023. doi:10.3390/v15071489
BibTeX
@article{Devan2023,
author = {Devan, Pooja and Tiong, Kai Le Ashley and Neo, Jean Ee and Mohan, Babu P and Wijarnpreecha, Karn and Tam, Yew Chong Steve and Coppola, Nicola and Preda, Carmen Monica and Wong, Yu Jun},
title = {Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15071489}
}
EUVIMED